Linaclotide

Routes
Oral (PO)
Half-Life (t½)
PO: 1h
Formula
C59H79N15O21S6
Molecular Weight
1526.74 g/mol
PubChem CID
16158208
Aliases
Linzess

Pharmacological Mechanism

GC-C (guanylate cyclase-C) agonist — raises intestinal cGMP → CFTR-mediated chloride / bicarbonate / water secretion into lumen. Approved for chronic idiopathic constipation + IBS-C. Minimal systemic absorption → DDI-light. Diarrhea is the main dose-limiting side effect.

Half-Life & Elimination Curve (PO: 1h)

100%50%25%12.5%0%0h0×t½1h1×t½2h2×t½3h3×t½4h4×t½5h5×t½0×t½ (0h): 100% remaining (~0.00898 µg/L)1×t½ (1h): 50% remaining (~0.00449 µg/L)2×t½ (2h): 25% remaining (~0.00225 µg/L)3×t½ (3h): 12.5% remaining (~0.00112 µg/L)4×t½ (4h): 6.3% remaining (~0.000561 µg/L)5×t½ (5h): 3.1% remaining (~0.000281 µg/L)
Plasma (PO)t½ Decay (1h)
  • 0×t½0h100% (0.00898 µg/L)
  • 1×t½1h50% (0.00449 µg/L)
  • 2×t½2h25% (0.00225 µg/L)
  • 3×t½3h12.5% (0.00112 µg/L)
  • 4×t½4h6.3% (0.000561 µg/L)
  • 5×t½5h3.1% (0.000281 µg/L)
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
Time to Peak (Tmax)1.69h
Est. Peak (Cmax)0.00898 µg/L
Clearance (CL)3.47 L/h
97% Washout (5×t½)5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References